RxDoctor Payments Data

Manish Lakhani, MD

Cardiovascular Disease · Winchester, VANPI 1043485964

Payments from drug & device makers

$894in general payments, 2019–2025

Across 41 payments — averaging $21.81 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$208
  • Philips North America LLC$103
  • Novartis$91
  • Boston Scientific$82
  • Boehringer Ingelheim$81
  • Johnson & Johnson$75
  • plus $254 from 9 others

What the payments were for

  • Food & beverage$894100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$894 in reported general payments places this provider in the 35th percentile of 548 cardiovascular disease providers in Virginia.

See all cardiovascular disease providers in Virginia

Medicare billing

Part B allowed, 2024
$270,908
Medicare patients
2,408
Services billed
4,296

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban443$501,732
EntrestoSacubitril/Valsartan60$80,437
XareltoRivaroxaban70$67,834
Repatha SureclickEvolocumab32$38,269
MultaqDronedarone Hcl21$38,107
Flecainide Acetate143$5,965
Metoprolol Succinate405$4,960
Ranolazine ErRanolazine33$4,947
Diltiazem 12hr ErDiltiazem Hcl17$3,952
Amiodarone Hcl112$3,811
Ezetimibe109$3,523
Diltiazem 24hr Er (Cd)Diltiazem Hcl56$3,238
Atorvastatin Calcium245$2,998
Potassium Chloride42$2,717
Carvedilol255$2,008

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$33$501,732443 claims
NovartisEntresto$91$80,43760 claims
Johnson & JohnsonXarelto$75$67,83470 claims
Sanofi-aventis U.S. LLCMultaq$23$38,10721 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 548 cardiovascular disease providers in Virginia.

Other cardiovascular disease in Winchester

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →